**LETTER**

**MIDN locus structural variants and Parkinson’s Disease risk**

Kimberley J. Billingsley, Sara Bandres-Ciga, Jinhui Ding, Dena Hernandez, J. Raphael Gibbs, Cornelis Blauwendraat & On behalf of the International Parkinson’s Disease Genomics Consortium (IPDGC)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 35 Convent Drive, Bethesda, 20892, Maryland, United states

Correspondence
Kimberley J. Billingsley, Laboratory of Neurogenetics, NIA, NIH, 35 Convent Drive, Bethesda, MD 20892-3707. Tel: +1 (301) 451-3832; Fax: +001 301 451 5466; E-mail: Kimberley.billingsley@nih.gov

Funding Information
This work was supported in part by the Intramural Research Programs of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Environmental Health Sciences both part of the National Institutes of Health, Department of Health and Human Services; project numbers 1ZIA-NS003154, Z01-AG000949-02, and Z01-ES101986. In addition, this work was supported by the Department of Defense (award WB1XWH-09-2-0128), and The Michael J Fox Foundation for Parkinson’s Research.

Received: 09 January 2020; Accepted: 21 February 2020

**Annals of Clinical and Translational Neurology** 2020; 7(4): 602–603
doi: 10.1002/acn3.51012

Dear Editor,

Based on a candidate gene analysis, Obara and colleagues previously reported an association between Parkinson’s disease (PD) and deletion structural variants (SV)s at the MIDN locus in the Japanese population.\(^1\) In their recent study, using genotyping data from a British cohort, Obara and colleagues further suggest MIDN as a confirmed and universal risk factor of PD.\(^2\)

To establish the pathogenicity of MIDN, as part of the International Parkinson’s Disease Genomics Consortium (IPDGC), we utilized the summary statistics from the most recent PD meta-analysis, which involved 37.7k PD cases, 18.6 U.K. biobank proxy-cases, and 1.4 million controls. Consequently, we did not identify an association with risk of PD at this locus based on common SNP variants (Fig. S1)\(^3\). In addition, we analyzed whole genome sequencing data (WGS) from eight cohorts totaling 3868 individuals (2742 PD cases and 1126 controls of European ancestry). SVs were genotyped from the WGS using the highly sensitive detection tool Manta.\(^4\) The only major deletion detected was of a reference Alu retrotransposon (GRCh38 chr19:1247064-1247368, MAF = 0.014); however, further analysis identified no significant association between the Alu deletion and risk for PD (\(P = 0.74, \beta = -0.03, SE = 0.22\) (Appendix S1). Four additional singleton deletions were detected, including deletions of three reference Alu retrotransposons and a 4822-bp deletion that was detected in a healthy control (Fig. S2 and Table S1).

Further, Obara and colleague reported deletions at the MIDN locus in 1.64% of controls. In view of this, we utilized gnomadSV, a comprehensive public SV database. This resource provides a call set of \(~445k\) SVs that were detected in 14,891 genomes, spanning four major global populations.\(^5\) In support of our WGS analysis, as shown in (Fig. S3) no common deletion SVs were detected in the general population.

In summary, we did not identify any PD-associated deletions within 100 kb of MIDN in the 3,868 individuals analyzed. SV calling using SNP genotyping data is notoriously difficult and it has been repeatedly reported that this method can result in a high false positive rate.\(^6\)–\(^8\) Due to this factor, SVs require functional validation, which was not presented for the MIDN deletions described in the Obara and colleagues’ studies. Therefore, the lack of validation of the reported SVs, supported by the lack of evidence of these events in both the gnomadSV data and our WGS analysis, suggests that the MIDN deletions reported require further study before they can be unequivocally associated with PD.

**Acknowledgments**

We would like to thank all of the subjects who donated their time and biological samples to be a part of this study. We also would like to thank all members of the International Parkinson Disease Genomics Consortium.
(IPDGC). See for a complete overview of members, acknowledgments and funding http://pdgenetics.org/partners. The authors would like to thank the Genome Aggregation Database (gnomAD) and the groups that provided exome and genome variant data to this resource. A full list of contributing groups can be found at https://gnomad.broadinstitute.org/about.

**Conflict of Interest**

The authors have nothing to disclose.

**References**

1. Obara Y, Imai T, Sato H, et al. Midnolin is a novel regulator of parkin expression and is associated with Parkinson’s Disease. Sci Rep 2017;7:5885.
2. Obara Y, Sato H, Nakayama T, et al. Midnolin is a confirmed genetic risk factor for Parkinson’s disease. Ann Clin Transl Neurol 2019;6:2205–2211. https://doi.org/10.1002/acn3.50914.
3. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019;18:1091–1102.
4. Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 2016;32:1220–1222.
5. Collins RL, Brand H, Karczewski KJ, et al. An open resource of structural variation for medical and population genetics. bioRxiv 2019:578674. https://doi.org/10.1101/578674.
6. Wineinger NE, Tiwari HK. The impact of errors in copy number variation detection algorithms on association results. PLoS One 2012;7:e32396.
7. Cameron DL, Di Stefano L, Papenfuss AT. Comprehensive evaluation and characterisation of short read general-purpose structural variant calling software. Nature Communications 2019;10.
8. Zhang D, Qian Y, Akula N, et al. Accuracy of CNV detection from GWAS data. PLoS One 2011;6:e14511.

**Supporting Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Appendix S1. Supplementary Methods.**

**Table S1.** Clinical and demographic characteristics of WGS data.

**Figure S1.** Locuszoom plot of the MIDN locus from the most recent PD meta-analysis involving 37.7 PD cases, 18.6 UK biobank proxy-cases and 1.4M controls shows no association with PD based on common variants.

**Figure S2.** IGV snapshot of a heterozygous 4,822bp deletion (illustrated in red) detected with MANTA in a healthy control individual.

**Figure S3.** Snapshot of the MIDN locus generated by the gnomadSV browser (https://gnomad.broadinstitute.org/region/19-1217850-1294000?dataset=gnomad_sv_r2_1).